Cardinal Health Experiences 31% Drop in Trading Volume Following February Spike, Now Placed 379th in Market Activity

Market Overview

On March 13, 2026, Cardinal Health (CAH) saw trading activity reach $0.31 billion, representing a 31% decrease compared to the previous day. The stock ended the session down 0.92%, placing it 379th in trading volume among listed companies. This drop followed a notable upswing in early February, when shares climbed 9.8% after Cardinal Health posted better-than-expected second-quarter results. The recent downturn reflects broader market trends and uncertainty stemming from the company’s latest financial disclosures.

Main Influences

Cardinal Health’s share movement in March 2026 was influenced by fluctuating earnings, strategic direction, and changing institutional attitudes. The company’s second-quarter report in February showed impressive growth: revenue jumped 18.8% year-over-year to $65.63 billion, and adjusted earnings per share rose 36% to $2.63, beating the consensus estimate of $2.31. This strong performance, along with a projected 13–15% increase for the full fiscal year, initially boosted investor optimism. However, the subsequent pullback in March signaled lingering doubts about the company’s ability to maintain momentum, especially after the fourth-quarter 2025 report revealed revenue below expectations despite a significant EPS beat of 13.85%.

Cardinal Health’s focus on innovation was evident through acquisitions such as Solaris Health and the launch of new products. Management reported a 19% rise in operating earnings to $719 million for Q2 2026 and forecasted 11–13% growth in its pharmaceutical division. These strategies reflect industry-wide efforts to streamline healthcare supply chains and expand specialty drug distribution. Despite robust financial results, the stock fell 2.4% following the Q2 announcement, suggesting investors remain cautious about short-term execution risks, particularly given competition from companies like McKesson Corporation.

Analyst opinions added complexity to the stock’s outlook. Cardinal Health held a “Moderate Buy” consensus, with an average price target of $245.67. UBS Group and Jefferies increased their targets to $260 and $270, respectively, citing strong long-term prospects. In contrast, Wall Street Zen downgraded its rating from “Strong Buy” to “Buy.” The Zacks Rank #2 (Buy) rating, backed by a 15% projected long-term earnings growth, stood in opposition to the Swiss National Bank’s decision to reduce its stake by 5.9% in the third quarter of 2025, highlighting caution among major investors.

The company’s dividend announcement provided some reassurance, with Cardinal Health declaring a quarterly payout of $0.5107 (yielding 0.9%). This move underscored its commitment to rewarding shareholders, and the payout ratio of 29.35% indicates potential for future increases without straining cash reserves. Analysts noted that, with a market capitalization of $51.6 billion, CAH is viewed as a stable option in turbulent markets, supported by a beta of 0.65, which suggests less volatility than the overall market.

Performance Comparison

Cardinal Health’s recent results against benchmarks and competitors reveal a mixed picture. Over the last three months, CAH outperformed the Dow Jones Industrial Average, rising 11% while the Dow fell 3.7%. Over the past year, CAH surged 74.2%, compared to the Dow’s 12.9% gain. However, McKesson’s 15.1% year-to-date rise and 47.4% increase over 52 weeks highlight ongoing competitive challenges. These factors indicate that, although Cardinal Health’s fundamentals are solid, its continued success will depend on effectively managing economic challenges and maintaining leadership in healthcare logistics innovation.